Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226805 · ClinicalTrials.gov registry record · Phase 2
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
A Phase 2 study of Acute Ischemic Stroke, sponsored by Basking Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT06226805 is a Phase 2 study of Acute Ischemic Stroke that is actively recruiting participants, run by Basking Biosciences. The registered enrollment target is 228 participants, below the 343-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06226805, a Phase 2 study of Acute Ischemic Stroke, is actively recruiting participants, sponsored by Basking Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BB-031
Study Locations (20)
California
- Mills Peninsula Medical Center - Burlingame
- MemorialCare Long Beach Medical Center - Long Beach
- California Pacific Medical Center - San Francisco
- Pacific Neurosciences Institute at Saint John's Physician Partners - Torrance
Ohio
- The Ohio State University - Columbus
- ProMedica Toledo Hospital - Toledo
- Mercy Health St. Vincent Medical Center - Toledo
Texas
- Valley Baptist Medical Center - Harlingen - Harlingen
- Memorial Hermann Hospital - Houston
Victoria
- Monash Medical Centre - Clayton
- The Royal Melbourne Hospital - Parkville
Arizona
- HonorHealth Bob Bove Neuroscience Institute - Scottsdale
Florida
- Baptist Health Medical Center - Jacksonville
Michigan
- Henry Ford Hospital - Detroit
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06226805
The ClinicalTrials.gov registry entry for NCT06226805 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 343-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (34% lower). The listed sponsor is Basking Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06226805 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT06226805 about?
NCT06226805 is a clinical study titled "Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)". The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug...
What is the current status of trial NCT06226805?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2024-07-31. Estimated completion is 2027-09.
What conditions does trial NCT06226805 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT06226805?
The interventions under investigation include: Placebo (DRUG), BB-031 (DRUG).
Who is sponsoring clinical trial NCT06226805?
This trial is sponsored by Basking Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226805 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
RECRUITING · Phase 2
-
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
COMPLETED · Phase 2
-
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.